Northwestern Mutual Wealth Management
SCNI

Northwestern Mutual Wealth Management’s Scinai Immunotherapeutics SCNI Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$712 – 4425
2025
Q4 		$712 Hold
1,000
– – ﹤0.01% 3679
2025
Q3 		$1.26K Buy
+1,000
New +$1.74K ﹤0.01% 3493

Other funds holding SCNI

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northwestern Mutual Wealth Management's SCNI Position: Q1 2026 in Review

Northwestern Mutual Wealth Management sold out of Scinai Immunotherapeutics (SCNI) in Q1 2026, closing a stake of 1,000 shares — an estimated $712 sold.

Northwestern Mutual Wealth Management first reported a position in SCNI in Q3 2025 and held it in 2 quarters. The position peaked at $1.26K in Q3 2025. 4 funds tracked by Wall St. Rank hold SCNI as of Q1 2026.

  • Northwestern Mutual Wealth Management reported no remaining Scinai Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 1,000 Scinai Immunotherapeutics shares in Q1 2026, an estimated $712.
  • Northwestern Mutual Wealth Management first reported a position in Scinai Immunotherapeutics in Q3 2025 and held it in 2 quarters.
  • Northwestern Mutual Wealth Management's Scinai Immunotherapeutics position peaked at $1.26K in Q3 2025.
  • 4 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.